Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Short-term Investments (2016 - 2017)

Historic Short-term Investments for Adma Biologics (ADMA) over the last 3 years, with Q4 2017 value amounting to $1.5 million.

  • Adma Biologics' Short-term Investments fell 7217.16% to $1.5 million in Q4 2017 from the same period last year, while for Dec 2017 it was $1.5 million, marking a year-over-year decrease of 7217.16%. This contributed to the annual value of $1.5 million for FY2017, which is 7217.16% down from last year.
  • Latest data reveals that Adma Biologics reported Short-term Investments of $1.5 million as of Q4 2017, which was down 7217.16% from $845389.0 recorded in Q3 2017.
  • Adma Biologics' 5-year Short-term Investments high stood at $6.4 million for Q4 2015, and its period low was $245000.0 during Q1 2017.
  • Moreover, its 3-year median value for Short-term Investments was $1.2 million (2017), whereas its average is $2.5 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first crashed by 1535.75% in 2016, then crashed by 7217.16% in 2017.
  • Quarter analysis of 3 years shows Adma Biologics' Short-term Investments stood at $6.4 million in 2015, then fell by 15.36% to $5.4 million in 2016, then plummeted by 72.17% to $1.5 million in 2017.
  • Its last three reported values are $1.5 million in Q4 2017, $845389.0 for Q3 2017, and $845389.0 during Q2 2017.